Markers of bone formation and bone resorption during two years of treatment with etidronate/placebo or etidronate/NaF in patients with established oseoporosis, treated with corticosteroids
| Baseline | 3 months | 6 months | 12 months | 18 months | 24 months | |
| BAP (placebo) | 15.1 (8.3) | 14.2 (5.6) | 17.3 (10.2) | 15.0 (5.3) | 15.8 (5.8) | 16.0 (5.1) |
| BAP (NaF) | 22.6 (14.2) | 21.2 (9.2) | 25.4 (14.0) | 28.3 (13.4) | 24.8 (12.7) | 25.2 (14.5) |
| Osteocalcin (placebo) | 15.3 (9.2) | 17.8 (20.6) | 13.6 (7.0) | 16.9 (11.7) | 16.0 (7.4) | 15.8 (7.3) |
| Osteocalcin (NaF) | 20.4 (10.7) | 18.8 (8.1) | 21.6 (12.7) | 20.3 (9.9) | 18.3 (6.7) | 19.8 (10.0) |
| Pyridinoline (total, placebo) | 55 (42) | 53 (41) | 51 (38) | 46 (19) | 42 (20) | 40 (21) |
| Pyridinoline (total, NaF) | 46 (23) | 45 (27) | 50 (28) | 44 (18) | 46 (23) | 49 (25) |
| Deoxypyridinoline (total, placebo) | 13.6 (9.8) | 11.1 (7.5) | 9.2 (5.6) | 10.2 (4.7) | 9.8 (5.8) | 10.5 (6.0) |
| Deoxypyridinoline (total, NaF) | 12.4 (4.0) | 10.1 (5.4) | 12.5 (5.7) | 11.9 (6.1) | 12.6 (7.7) | 15.6 (16.7) |
No statistically dignificant differences in comparison with baseline in both groups. Data shown as mean (SD).